


SUPPLEMENTARY DATA

Supplementary Figure 1. Insulin resistance expressed as HOMA-IR (**panel A**), Adipo-IR (**panel B**), and Matsuda Index (**panel C**) in Caucasian and African- American patients. Cauc: Caucasian; AA: African-American; HOMA-IR: homeostatic model assessment of insulin resistance; Adipo-IR: adipose tissue insulin resistance index; OGTT: oral glucose tolerance test.



Supplementary Table 1. Sensitivity analysis

	Prevalence of NAFLD (%)		Prevalence of NASH among NAFLD (%)		Inflammation grade		Ballooning grade		Fibrosis stage		Plasma triglycerides (mg/dl)		Plasma HDL-C (mg/dl)	
	Cauc	AA	Cauc	AA	Cauc	AA	Cauc	AA	Cauc	AA	Cauc	AA	Cauc	AA
Overall cohort (n=201)	51.9	25.0	73.3	57.1	1.82 ± 0.51	1.75 ± 0.44	1.20 ± 0.52	1.06 ± 0.25	1.24 ± 1.10	1.19 ± 0.91	144 (97-210)	97 (71-140)	39 ± 10	46 ± 16
	p = 0.003		p = 0.12		p = 0.63		p = 0.31		p = 0.87		p < 0.001		p < 0.001	
Patients with T2DM (n= 152)	68.0	34.7	75.4	61.1	1.84 ± 0.53	1.82 ± 0.40	1.19 ± 0.50	1.09 ± 0.30	1.30 ± 1.12	1.55 ± 0.82	145 (96-223)	99 (77-139)	39 ± 10	45 ± 15
	p < 0.001		p = 0.24		p = 0.91		p = 0.55		p = 0.51		p < 0.001		p = 0.007	
Excluding patients on insulin (n= 177)	72.3	41.4	73.9	54.1	1.82 ± 0.52	1.69 ± 0.48	1.20 ± 0.53	1.08 ± 0.28	1.16 ± 1.08	1.15 ± 0.99	144 (100-207)	106 (70-145)	40 ± 10	47 ± 16
	p < 0.001		p = 0.07		p = 0.41		p = 0.44		p = 0.99		p < 0.001		p < 0.001	
Patients with high total body fat* (n= 81)	79.7	52.9	76.6	54.5	1.72 ± 0.51	1.67 ± 0.52	1.28 ± 0.51	1.00 ± 0.00	0.97 ± 1.06	1.33 ± 0.82	158 (104-215)	90 (76-133)	41 ± 9	48 ± 18
	p = 0.03		p = 0.16		p = 0.81		p = 0.20		p = 0.43		p < 0.001		p = 0.03	
Only obese individuals (n= 158)	76.2	45.6	76.9	57.7	1.78 ± 0.51	1.73 ± 0.46	1.20 ± 0.53	1.07 ± 0.26	1.14 ± 1.05	1.13 ± 0.92	151 (100-220)	104 (71-148)	39 ± 9	45 ± 15
	p < 0.001		p = 0.07		p = 0.75		p = 0.36		p = 0.98		p < 0.001		p = 0.002	

* Defined as ≥35.4% based on total body fat median.